CureVac anticipates funding will last until 2028
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 24 2025
0mins
Cash Position: As of September 30, 2025, cash and cash equivalents amounted to EUR 416.1 million, down from EUR 481.7 million at the end of 2024.
Use of Cash: The cash was primarily utilized for operating activities, focusing on research and development in oncology precision immunotherapies and mRNA technology.
Decrease in Cash Outflow: Cash outflow significantly decreased compared to the same period in 2024, attributed to the absence of extraordinary payments from the previous year and cost-saving measures from a strategic restructuring.
Future Outlook: The company reaffirms its expected cash runway extending into 2028.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVAC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVAC
About CVAC
CureVac CureVac NV, formerly CureVac AG, is a Germany-based clinical-stage biopharmaceutical company. The Company develops transformative medicines based on messenger ribonucleic acid, or mRNA. The Company's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The Company's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Honeywell Lowers FY2025 EPS Guidance to $9.70-$9.80 Amid Business Unit Discontinuation
- Guidance Reduction: Honeywell confirmed the discontinuation of its Advanced Materials business unit and lowered its FY2025 adjusted EPS guidance from $10.60-$10.70 to $9.70-$9.80, reflecting significant market challenges and pressure on profitability.
- Sales Forecast Cut: The company also reduced its sales guidance from $40.70 billion-$40.90 billion to $37.50 billion-$37.70 billion, indicating a cautious outlook on future market demand, which may impact investor confidence.
- Stock Price Reaction: In pre-market trading, Honeywell's shares fell 2.1% to $195.00, reflecting market concerns about the company's outlook and potentially increasing selling pressure among investors in the short term.
- Industry Impact: The discontinuation of this business unit and the guidance reduction may negatively affect Honeywell's market position in the materials sector, forcing the company to reassess its strategic direction to cope with intensifying competition.
Continue Reading
Clearwater Analytics (CWAN) Acquired by Private Equity Consortium for $8.4 Billion
- Acquisition Announcement: A consortium of private equity firms led by Permira and Warburg Pincus has announced a deal to acquire Clearwater Analytics for approximately $8.4 billion, including debt, indicating strong market interest in investment and accounting software companies.
- Stock Price Reaction: Clearwater Analytics shares surged 7.6% to $23.93 in pre-market trading, reflecting positive investor sentiment regarding the acquisition news, which may enhance the company's future market performance.
- Market Impact: This acquisition not only provides Clearwater Analytics with financial backing but also has the potential to accelerate its technological innovation and market expansion, strengthening its position in the highly competitive software industry.
- Industry Trend: With private equity firms continuing to invest in the software sector, more similar transactions are expected, further consolidating market resources and enhancing industry competitiveness.
Continue Reading